GoAI
Get started
Kelfred Holdings Limited logo

Kelfred Holdings Limited

1134.HK

HKSEHealthcareMedical - Instruments & Supplies

Open in GoAI

Latest quote

HK$0.241

−HK$0.001 · -0.41%

Aug 21, 6:08 PM HKTData delayed

1134.HK company overview

Historical prices · Market data may be delayed.

Company profile

Company website

Kelfred Holdings Limited functions as an investment holding entity primarily engaged in the creation and sale of eyewear. The firm produces a diverse array of spectacle frames and sunglasses, largely leveraging original design manufacturing (ODM) and original equipment manufacturing (OEM) models. Its comprehensive offerings span from product conceptualization and sourcing of raw materials to the manufacturing process, rigorous quality assurance, packaging, and final distribution. Additionally, Kelfred markets its proprietary 'Miga' brand items and participates in the general trading of eyewear merchandise. Established in 1986 and headquartered in Sha Tin, Hong Kong, the company boasts a significant international presence, conducting operations across the People's Republic of China, Italy, the United Kingdom, the Netherlands, France, Spain, Hungary, the United States, and other global markets.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
HK
CEO
Kwan Yu Kwok
Listed since
Jul 16, 2019
Employees
752

Market position

Day range

Current HK$0.241

52-week range

Current HK$0.241

Open
HK$0.241
Previous close
HK$0.242
Volume
4K
0× average
Average volume
993.79K
Average daily volume
Market cap
120.5M HKD
Beta
-0.2
Market reference 1
50-day average
HK$0.3091
-22.04% below average
200-day average
HK$0.2956
-18.48% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
83.46M HKD
P/E (TTM)
-7.98×
P/B (TTM)
0.81×
P/S (TTM)
0.24×
EV / EBITDA
67.9×
Earnings yield
-12.29%
Free cash flow yield
18.96%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
11.86%
Operating margin
-2.22%
Net margin
-3.02%
Return on equity
-10.18%
Return on assets
-5.35%
Return on invested capital
-7.07%

Financial health

Debt / equity
0.06×
Current ratio
1.91×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends18%10%2%-7%Gross margin, FY2021: 15.74%Gross margin, FY2022: 16.33%Gross margin, FY2023: 14.49%Gross margin, FY2024: 9.85%Gross margin, FY2025: 11.86%Operating margin, FY2021: -1.48%Operating margin, FY2022: 2.45%Operating margin, FY2023: 0.97%Operating margin, FY2024: -4.29%Operating margin, FY2025: -2.22%Net margin, FY2021: -0.49%Net margin, FY2022: 1.97%Net margin, FY2023: 0.35%Net margin, FY2024: -4.77%Net margin, FY2025: -3.02%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 15.74%. Gross margin FY2022 16.33%. Gross margin FY2023 14.49%. Gross margin FY2024 9.85%. Gross margin FY2025 11.86%. Operating margin FY2021 -1.48%. Operating margin FY2022 2.45%. Operating margin FY2023 0.97%. Operating margin FY2024 -4.29%. Operating margin FY2025 -2.22%. Net margin FY2021 -0.49%. Net margin FY2022 1.97%. Net margin FY2023 0.35%. Net margin FY2024 -4.77%. Net margin FY2025 -3.02%.

Income trends

Revenue

500.25M HKD+10.29%

Operating income

−11.09M HKD+42.99%

Net income

−15.12M HKD+30.11%
Income trends across reported periods552.44M HKD343.69M HKD134.93M HKD−73.82M HKDRevenue, FY2021: 434.73M HKDRevenue, FY2022: 465.43M HKDRevenue, FY2023: 393.28M HKDRevenue, FY2024: 453.58M HKDRevenue, FY2025: 500.25M HKDOperating income, FY2021: −6.43M HKDOperating income, FY2022: 11.4M HKDOperating income, FY2023: 3.83M HKDOperating income, FY2024: −19.46M HKDOperating income, FY2025: −11.09M HKDNet income, FY2021: −2.14M HKDNet income, FY2022: 9.18M HKDNet income, FY2023: 1.39M HKDNet income, FY2024: −21.63M HKDNet income, FY2025: −15.12M HKDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 434.73M HKD. Revenue FY2022 465.43M HKD. Revenue FY2023 393.28M HKD. Revenue FY2024 453.58M HKD. Revenue FY2025 500.25M HKD. Operating income FY2021 −6.43M HKD. Operating income FY2022 11.4M HKD. Operating income FY2023 3.83M HKD. Operating income FY2024 −19.46M HKD. Operating income FY2025 −11.09M HKD. Net income FY2021 −2.14M HKD. Net income FY2022 9.18M HKD. Net income FY2023 1.39M HKD. Net income FY2024 −21.63M HKD. Net income FY2025 −15.12M HKD.
Metric (HKD)FY2025FY2024FY2023FY2022FY2021
Revenue500.25M HKD453.58M HKD393.28M HKD465.43M HKD434.73M HKD
Cost of goods sold440.94M HKD408.92M HKD336.31M HKD389.41M HKD366.29M HKD
Gross profit59.31M HKD44.67M HKD56.98M HKD76.02M HKD68.44M HKD
Selling, general, and administrative76.76M HKD76.94M HKD77.25M HKD78.25M HKD74.69M HKD
Operating expenses70.4M HKD64.12M HKD53.15M HKD64.62M HKD69.55M HKD
Interest income9K HKD17K HKD25K HKD25K HKD26K HKD
Interest expense2.64M HKD1.98M HKD1.68M HKD740K HKD508K HKD
Depreciation and amortization8.54M HKD6.64M HKD10.39M HKD9.69M HKD14.18M HKD
Operating income−11.09M HKD−19.46M HKD3.83M HKD11.4M HKD−6.43M HKD
Net income−15.12M HKD−21.63M HKD1.39M HKD9.18M HKD−2.14M HKD

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-0.02

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates0.070.02-0.02-0.06Q3 '20Q3 '22Q1 '23Q3 '23Q1 '24Q3 '24
Q3 2020, reported Aug 28, 2020: actual -0.017, estimate —, surprise —, Comparison unavailable. Q3 2022, reported Aug 30, 2022: actual 0.026, estimate —, surprise —, Comparison unavailable. Q1 2023, reported Mar 30, 2023: actual -0.007, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 29, 2023: actual 0.011, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 26, 2024: actual -0.008, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 26, 2024: actual -0.025, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates260.31M214.9M169.49M124.08MQ3 '20Q3 '22Q1 '23Q3 '23Q1 '24Q3 '24
Q3 2020, reported Aug 28, 2020: actual 134.09M HKD, estimate —, surprise —, Comparison unavailable. Q3 2022, reported Aug 30, 2022: actual 250.3M HKD, estimate —, surprise —, Comparison unavailable. Q1 2023, reported Mar 30, 2023: actual 215.13M HKD, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 29, 2023: actual 195.08M HKD, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 26, 2024: actual 198.2M HKD, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 26, 2024: actual 197.41M HKD, estimate —, surprise —, Comparison unavailable.

Corporate actions

Corporate action history

Dividend

Ex-dividend May 26, 2020

HK$0.02

Special

Record May 27, 2020 · Payment Jun 22, 2020

1134.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.8

-3.89%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.74

-3.03%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$222.4

-2.46%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.60

-4.71%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.22

-5.62%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$100.2

-2.15%

Continue in GoAI

Research 1134.HK

research.disclaimer